Roche: trial results for breast cancer drug
(CercleFinance.com) - Roche's Tecentriq, in combination with chemotherapy (including Abraxane) has met the primary endpoint of improving the complete pathological response, regardless of PD-L1 status, as an initial treatment for people with early triple negative breast cancer.
This announcement follows the IMpassion031 Phase III study evaluating Tecentriq.
The IMpassion031 data will be discussed with health authorities worldwide, including the US FDA and the European Medicines Agency.
Tecentriq is the only anti-cancer immunotherapy approved for the treatment of metastatic triple-negative breast cancer, a very aggressive and difficult-to-treat form of breast cancer.
"Triple-negative breast cancer remains an aggressive disease with high rates of recurrence," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
"Adding Tecentriq to chemotherapy now has the potential to help women with TNBC at multiple different stages of the disease."
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This announcement follows the IMpassion031 Phase III study evaluating Tecentriq.
The IMpassion031 data will be discussed with health authorities worldwide, including the US FDA and the European Medicines Agency.
Tecentriq is the only anti-cancer immunotherapy approved for the treatment of metastatic triple-negative breast cancer, a very aggressive and difficult-to-treat form of breast cancer.
"Triple-negative breast cancer remains an aggressive disease with high rates of recurrence," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
"Adding Tecentriq to chemotherapy now has the potential to help women with TNBC at multiple different stages of the disease."
Copyright (c) 2020 CercleFinance.com. All rights reserved.